top of page

Swiss Biotech Day: Basel based BioVersys successfully completed an approximately CHF 80 million IPO in February to advance its work in antimicrobial resistance

May 6, 2025
1 min read

Co-Founder & CEO Marc Gitzinger describes the success factors behind the IPO and walks us through the company's two lead programs. Plus, his thoughts on the evolving business model for this field.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page